Glenmark gets USFDA nod to mkt Gabapentin

Glenrnark Pharmaceuticals Inc, USA (GPI), the wholly-owned US-based subsidiary of Glenmark Pharmaceuticals, has received US FDA approval to market Gabapentin oral tablets 600 mg and 800 mg.

According to a release issued by Glenmark to the BSE today, Gabapentin belongs to a category of anti-convulsants, and is prescribed to help control epileptic seizures. "It is also widely used to relieve different kinds of pain and even psychiatric disorders. The drug enjoys a generic market size of $328 million," the release added.

The company manufactures the drug at its solid-oral formulation facility at Goa and will commence shipments of Gabapentin immediately, the release said.